Asia Pacific Radiopharmaceuticals Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2031 |
 Taille du marché (année de référence) |
USD 1.76 Billion |
 Taille du marché (année de prévision) |
USD 2.73 Billion |
 TCAC |
% |
| Principaux acteurs du marché |
Segmentation du marché des produits radiopharmaceutiques en Asie-Pacifique, par type (produits radiopharmaceutiques diagnostiques et produits radiopharmaceutiques thérapeutiques), application (diagnostique et thérapeutique), type de médicament (génériques et de marque), source (réacteurs nucléaires, cyclotrons et autres), utilisateur final (hôpitaux, centres de diagnostic, instituts de recherche sur le cancer, centres de chirurgie ambulatoire et autres) - Tendances et prévisions de l'industrie jusqu'en 2031.
Analyse et taille du marché des produits radiopharmaceutiques en Asie-Pacifique
Le marché des implants cornéens en Asie-Pacifique est influencé par plusieurs facteurs, notamment la prévalence croissante des maladies cornéennes, le vieillissement croissant de la population, les progrès technologiques, la demande croissante de procédures mini-invasives, la sensibilisation croissante à la transplantation cornéenne, les initiatives et financements gouvernementaux, l'adoption croissante des lentilles hybrides et toriques, la popularité croissante des procédures de réticulation, l'élargissement des indications pour les implants cornéens et un paysage concurrentiel qui favorise l'innovation. Ces facteurs stimulent collectivement la demande d'implants cornéens, en particulier dans les pays développés, car les patients recherchent des traitements efficaces pour les troubles de la vision et des affections telles que le kératocône, la dystrophie de Fuchs et la kératopathie bulleuse pseudophaque.
Data Bridge Market Research analyse que le marché des produits radiopharmaceutiques en Asie-Pacifique devrait atteindre 2,73 milliards USD d'ici 2031, contre 1,76 milliard USD en 2023, avec un TCAC de 5,7 % au cours de la période de prévision de 2024 à 2031.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Années historiques |
2022 (Personnalisable 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en milliards USD |
|
Segments couverts |
Type (radiopharmaceutiques diagnostiques et thérapeutiques), application (diagnostique et thérapeutique), type de médicament (génériques et de marque), source (réacteurs nucléaires, cyclotrons et autres), utilisateur final (hôpitaux, centres de diagnostic, instituts de recherche sur le cancer, centres de chirurgie ambulatoire et autres) |
|
Pays couverts |
Chine, Japon, Australie, Corée du Sud, Singapour, Inde, Indonésie, Philippines, Malaisie, Vietnam et reste de l'Asie-Pacifique |
|
Acteurs du marché couverts |
Cardinal Health, Advanced Accelerator Applications, Lantheus, Curium, GE HealthCare, Jubilant Radiopharma, (une société Jubilant Pharma), Ansto, Eli Lilly And Company, Bayer AG, Siemens Healthcare Gmbh, Chine, isotope & Radiation Corporation, Bracco, NTP, Eckert & Ziegler, Eczacıbaşı-Monrol, IBA Worldwide, BWX Technologies. Inc, Isotope JSC, Sterigenics US, LLC entre autres. |
Définition du marché
A Radiopharmaceuticals contains a radioactive substance in association with one or more ingredients and that is intended to diagnose, stage a disease, monitor treatment, or provide therapy.. Radiopharmaceuticals include a group of radioactive agents used for either diagnostic or therapeutic interventions. Radiopharmaceuticals are the pharmaceuticals that incorporate a radionuclide. Most radiopharmaceuticals are a combination of a radioactive nuclide or radionuclide, and a biologically active molecule or drug that acts as a carrier and determines localization and biodistribution.
Asia-Pacific Radiopharmaceuticals Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
The Growing Demand for Radiopharmaceuticals in Diagnostics and Clinical Use
Radiopharmaceuticals have become essential in helping to diagnose organs and treat pathological disorders. They are utilized in diagnostic imaging and radiotherapy. Diagnostic radiopharmaceuticals possess no pharmacological effects and their administration is also not considered to be associated with relevant clinical side effects.
The number of radiopharmaceuticals in clinical use is rapidly growing, thus, allowing the medical community better access to detail information on the characteristics of the different types of tumors. Radionuclides are also gaining importance by providing palliative and curative treatment for an increasing number of malignant diseases.
For instance,
- In February 2024 , According to the Article published by International Atomic Energy Agency, Radiopharmaceuticals are used in diagnosis by administering radioactive compounds that emit gamma photons, which penetrate the body and are detected by external cameras to produce images of target tissues or organs. These images help in detecting tumors, assessing organ function, and diagnosing conditions like cancer and cardiovascular diseases. Unlike X-rays, a waiting period is often required for the radiopharmaceutical to reach its target, enabling precise imaging
The Increasing Need for Pharmaceutical Products Across Varied Therapeutic Areas
The growing cases of new diseases across the globe are a major concern for healthcare providers. Pharma and biopharmaceuticals companies are putting in everyday effort to tackle the challenge associated with various diseases. The increasing interest of market players willing to provide a wide range of radiopharmaceuticals products to be used in a different formulation pushes the market growth.
La prévalence croissante des maladies, liée à l'âge, au type de population, à l'hérédité génétique et à la propagation des maladies infectieuses chroniques dans le monde, est le principal facteur à l'origine de la demande croissante de produits radiopharmaceutiques. Ils ont été décrits pour le diagnostic des maladies inflammatoires chroniques et plusieurs peptides, ligands récepteurs et anticorps monoclonaux ont été radiomarqués, ce qui permet la visualisation in vivo des processus inflammatoires au niveau cellulaire et moléculaire.
Par exemple,
- En février 2019, selon un article du NCBI, un certain nombre de développements récents suggèrent que la thérapie radiopharmaceutique est sur le point d'émerger comme une modalité thérapeutique importante et largement reconnue, capable de délivrer un rayonnement cytotoxique aux cellules tumorales sans provoquer de toxicité prohibitive pour les tissus normaux.
Opportunité
L'augmentation des dépenses de recherche et développement dans le domaine des produits radiopharmaceutiques
Les progrès technologiques comprennent l'amélioration de la stabilité et de la résistance des produits pharmaceutiques traditionnels. Les sociétés biotechnologiques et pharmaceutiques investissent en permanence dans la recherche et le développement pour offrir des services innovants en matière de diagnostic et de médicaments aux clients et renforcer leur présence sur le marché. Les produits radiopharmaceutiques jouent un rôle dynamique dans le développement clinique. Alors que l'industrie du diagnostic est dans un état de fluctuation constant en raison de la mise en œuvre de nouvelles technologies sur le marché, les industries pharmaceutiques et biotechnologiques continuent de croître en raison de l'augmentation des investissements dans les sociétés radiopharmaceutiques ainsi que des fusions et acquisitions et de l'adoption d'innovations dans les technologies d'imagerie pour soutenir les essais cliniques pour diverses maladies .
Retenue/Défi
- Risques potentiels associés aux produits radiopharmaceutiques
L'exposition chronique par inhalation à l'uranium et au radon chez l'homme a été associée à des effets respiratoires, tels que des maladies pulmonaires chroniques, tandis que l'exposition au radium a entraîné une leucopénie aiguë, une anémie, une nécrose de la mâchoire et d'autres effets. L'élément radioactif radium ressemble à une molécule de calcium qui s'incorpore dans les zones du corps où le renouvellement osseux est élevé, comme les zones des organes où le cancer se développe. Outre cela, quelques risques procéduraux sont également impliqués avec les produits radiopharmaceutiques.
Développements récents
• En octobre 2022, Cardinal Health a été reconnue par Forbes comme l'une des meilleures grandes entreprises d'Amérique en 2022, à la suite d'une enquête indépendante menée auprès d'environ 60 000 employés américains travaillant pour des entreprises américaines. L'entreprise estime que cela l'inspirera et motivera ses employés
- En décembre 2022, Novartis a reçu l'approbation de la Commission européenne pour Pluvicto en tant que première thérapie ciblée par radioligand pour le traitement du cancer de la prostate. L'entreprise estime que cela contribuera à faire progresser un large portefeuille de thérapies par radioligand pour traiter le cancer
- En août 2024, Lantheus Holdings, Inc. (« Lantheus »), la société leader axée sur les produits radiopharmaceutiques qui s'engage à permettre aux cliniciens de détecter, de combattre et de suivre les maladies afin d'offrir de meilleurs résultats aux patients, a annoncé aujourd'hui qu'Oliver Sartor, MD, directeur des essais radiopharmaceutiques et professeur d'oncologie médicale à la Mayo Clinic de Rochester, Minnesota, fera une présentation orale, comprenant des données cliniques supplémentaires issues de la lecture initiale du PNT2002 de décembre 2023, lors de la réunion annuelle de la Société européenne d'oncologie médicale (ESMO) à Barcelone le dimanche 15 septembre 2024
- En juillet 2024, l'ANSTO et l'Université de Wollongong ont développé un dispositif Quad-MOSFET pour le contrôle qualité en temps réel de la thérapie par capture de neutrons au bore. Cet outil innovant améliore la précision en distinguant les niveaux d'énergie des neutrons, améliorant ainsi la sécurité et l'efficacité du traitement du cancer
Portée du marché des produits radiopharmaceutiques en Asie-Pacifique
Le marché des produits radiopharmaceutiques de la région Asie-Pacifique est segmenté en huit segments notables en fonction du type, de l'application, du type de médicament, de la source et de l'utilisateur final. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et les différences entre vos marchés cibles.
Taper
- Produits radiopharmaceutiques diagnostiques
- Produits radiopharmaceutiques thérapeutiques
Sur la base du type, le marché des produits radiopharmaceutiques de la région Asie-Pacifique est segmenté en produits radiopharmaceutiques diagnostiques et produits radiopharmaceutiques thérapeutiques.
Application
- Diagnostique
- Thérapeutique
Sur la base des applications, le marché des produits radiopharmaceutiques de l’Asie-Pacifique est segmenté en produits diagnostiques et thérapeutiques.
Type de médicament
- De marque
- Génériques
Sur la base du type de médicament, le marché des produits radiopharmaceutiques de la région Asie-Pacifique est segmenté en génériques et en produits de marque.
Source
- Réacteurs nucléaires
- Cyclotrons
- Autres
Sur la base de la source, le marché des produits radiopharmaceutiques de la région Asie-Pacifique est segmenté en réacteurs nucléaires, cyclotrons et autres.
Utilisateur final
- Hôpitaux
- Centres de diagnostic
- Instituts de recherche sur le cancer
- Centres de chirurgie ambulatoire
- Autres
Sur la base de l’utilisateur final, le marché des produits radiopharmaceutiques de la région Asie-Pacifique est segmenté en hôpitaux, centres de diagnostic, instituts de recherche sur le cancer, centres de chirurgie ambulatoire et autres.
Analyse/perspectives régionales du marché des produits radiopharmaceutiques en Asie-Pacifique
Le marché des produits radiopharmaceutiques de la région Asie-Pacifique est analysé et des informations et tendances sur la taille du marché sont fournies en fonction du type, de l’application, du type de médicament, de la source et de l’utilisateur final.
Les pays couverts dans ce rapport de marché sont la Chine, le Japon, l’Australie, la Corée du Sud, Singapour, l’Inde, l’Indonésie, les Philippines, la Malaisie, le Vietnam et le reste de l’Asie-Pacifique.
La Chine devrait dominer le marché de l'Asie-Pacifique en raison de sa population importante, de l'augmentation des dépenses de santé, de l'expansion de l'industrie pharmaceutique, de la sensibilisation croissante des consommateurs et de la demande de traitements, associés à une infrastructure de soins de santé en développement et à une prévalence croissante.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces du porteur, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques d'Asie-Pacifique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et des routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des produits radiopharmaceutiques en Asie-Pacifique
Le paysage concurrentiel du marché des produits radiopharmaceutiques en Asie-Pacifique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence régionale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché des produits radiopharmaceutiques en Asie-Pacifique.
Français Certains des principaux acteurs opérant sur le marché des produits radiopharmaceutiques en Asie-Pacifique sont Cardinal Health, Advanced Accelerator Applications, Lantheus, Curium, GE HealthCare, Jubilant Radiopharma, (A Jubilant Pharma Company), Ansto, Eli Lilly And Company, Bayer AG, Siemens Healthcare Gmbh, Chine, isotope & Radiation Corporation, Bracco, NTP, Eckert & Ziegler, Eczacıbaşı-Monrol, IBA Worldwide, BWX Technologies. Inc, Isotope JSC, Sterigenics US, LLC entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC RADIOPHARMACEUTICALS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET TESTING TYPE COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE
6.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS
6.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS
6.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS
6.3 OPPORTUNITIES
6.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS
6.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION
6.4 CHALLENGES
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
6.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE
7 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 BRANDED
7.3 GENERICS
8 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS
8.2.1 PET RADIOPHARMACEUTICALS
8.2.1.1 F-18
8.2.1.2 RU-82
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS
8.2.2 SPECT RADIOPHARMACEUTICALS
8.2.2.1 TECHNETIUM-99M
8.2.2.2 GALLIUM-67
8.2.2.3 IODINE-123
8.2.2.4 THALLIUM-201
8.2.2.5 OTHER SPECT ISOTOPES
8.3 THERAPEUTIC RADIOPHARMACEUTICALS
8.3.1 BRACHYTHERAPY ISOTOPES
8.3.1.1 IODINE-125
8.3.1.2 PALLADIUM-103
8.3.1.3 CESIUM-131
8.3.1.4 IRIDIUM-192
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES
8.3.2 BETA EMITTERS
8.3.2.1 IODINE-131
8.3.2.2 LUTHETIUM-177
8.3.2.3 SAMARIUM-153
8.3.2.4 YTTRIUM-90
8.3.2.5 RHENIUM-186
8.3.2.6 OTHER BETA EMITTERS
8.3.3 ALPHA EMITTERS
8.3.3.1 RA-223
8.3.3.2 OTHERS
9 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 DIAGNOSTIC
9.2.1 ONCOLOGY
9.2.2 CARDIOLOGY
9.2.3 NEUROLOGY
9.2.4 BONE SCANS
9.2.5 THYROID APPLICATIONS
9.2.6 PULMONARY SCANS
9.2.7 OTHERS
9.3 THERAPEUTIC
9.3.1 THYROID INDICATIONS
9.3.2 BONE METASTASIS
9.3.3 LYMPHOMA
9.3.4 ENDOCRINE TUMORS
9.3.5 OTHER INDICATIONS
10 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NUCLEAR REACTORS
10.3 CYCLOTRONS
10.4 OTHERS
11 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC
11.2.2 PRIVATE
11.2.2.1 DIAGNOSTIC CENTERS
11.2.2.2 CANCER RESEARCH INSTITUTES
11.2.2.3 AMBULATORY SURGICAL CENTERS
11.2.2.4 OTHERS
12 APAC RADIOPHARMACEUTICALS MARKET, BY COUNTRY
12.1 ASIA-PACIFIC
13 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 CARDINAL HEALTH
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 LANTHEUS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 CURIUM
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENT
15.5 GE HEALTHCARE
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ANSTO
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT UPDATES
15.7 BAYER AG
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 BRACCO
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BWX TECHNOLOGIES. INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 CHINA ISOTOPE & RADIATION CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 ELI LILLY AND COMPANY
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 ECKERT & ZIEGLER
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 GLOBAL MEDICAL SOLUTIONS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 ECZACIBAŞI-MONROL
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 IBA WORLDWIDE
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 ISOTOPE JSC
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 MALLINCKRODT PHARMACEUTICALS
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT UPDATES
15.19 NTP
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 SIEMENS HEALTHCARE GMBH
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENT
15.21 STERIGENICS U.S., LLC – A SOTERA HEALTH COMPANY
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 2 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 3 ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 6 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 7 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 9 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 10 ASIA-PACIFIC THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 13 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 14 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 16 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 17 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 19 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 20 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 21 ASIA-PACIFIC DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 ASIA-PACIFIC THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 24 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 27 CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 CHINA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 30 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 31 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 32 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 34 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 35 CHINA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 38 100
TABLE 39 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 40 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 41 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 42 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 43 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 45 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 46 CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 47 CHINA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 CHINA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 CHINA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 50 CHINA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 51 CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 52 CHINA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 57 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 58 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 60 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 61 AUSTRALIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 64 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 65 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 67 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 68 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 70 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 71 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 72 AUSTRALIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 AUSTRALIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 75 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 76 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 77 AUSTRALIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 82 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 83 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 85 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 86 JAPAN THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 89 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 90 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 92 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 93 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 94 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 95 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 96 JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 97 JAPAN DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 JAPAN THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 JAPAN RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 100 JAPAN RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 101 JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 102 JAPAN HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 SOUTH KOREA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 107 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 108 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 110 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 111 SOUTH KOREA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 112 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 114 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 115 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 117 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 118 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 119 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 120 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 121 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 122 SOUTH KOREA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 SOUTH KOREA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 125 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 126 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 127 SOUTH KOREA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 SINGAPORE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 132 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 133 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 135 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 136 SINGAPORE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 139 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 140 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 141 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 142 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 143 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 145 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 146 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 147 SINGAPORE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 SINGAPORE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 150 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 151 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 SINGAPORE HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 153 INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 INDIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 157 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 158 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 160 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 161 INDIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 163 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 164 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 165 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 167 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 168 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 170 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 171 INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 172 INDIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 INDIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 INDIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 175 INDIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 176 INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 177 INDIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 INDONESIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 182 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 183 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 185 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 186 INDONESIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 189 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 190 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 192 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 193 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 195 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 196 INDONESIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 197 INDONESIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 INDONESIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 199 INDONESIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 200 INDONESIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 201 INDONESIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 202 INDONESIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 PHILIPPINES DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 207 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 208 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 210 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 211 PHILIPPINES THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 212 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 213 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 214 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 215 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 217 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 218 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 220 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 221 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 222 PHILIPPINES DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 PHILIPPINES THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 225 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 226 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 227 PHILIPPINES HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 THAILAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 THAILAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 232 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 233 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 234 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 235 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 236 THAILAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 239 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 240 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 241 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 242 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 243 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 245 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 246 THAILAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 247 THAILAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 THAILAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 THAILAND RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 250 THAILAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 251 THAILAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 252 THAILAND HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 253 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 MALAYSIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 257 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 258 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 260 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 261 MALAYSIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 263 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 264 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 265 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 267 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 268 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 269 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 270 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 271 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 272 MALAYSIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 MALAYSIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 274 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 275 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 276 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 277 MALAYSIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 VIETNAM RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 VIETNAM DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 282 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 283 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 285 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 286 VIETNAM THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 287 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 288 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 289 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 290 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 292 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 293 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 294 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 295 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 296 VIETNAM RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 297 VIETNAM DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 298 VIETNAM THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 299 VIETNAM RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 300 VIETNAM RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 301 VIETNAM RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 302 VIETNAM HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
Liste des figures
FIGURE 1 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 11 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET:
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 THE RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 15 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, 2023
FIGURE 18 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 19 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, 2023
FIGURE 22 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 23 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 24 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2023
FIGURE 26 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 27 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 28 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2023
FIGURE 30 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2024-2031 (USD MILLION)
FIGURE 31 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, CAGR (2024-2031)
FIGURE 32 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, 2023
FIGURE 34 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 35 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 36 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 APAC RADIOPHARMACEUTICALS MARKET BY SNAPSHOT
FIGURE 38 AISA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
